Canada Life’s Pliant Therapeutics PLRX Stock Holding History

Canada Life’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,486	Closed	-$7K	–	1986
2025 Q1	$7K	Hold	5,486	–	–	﹤0.01%	1992
2024 Q4	$72K	Hold	5,486	–	–	﹤0.01%	1858
2024 Q3	$62K	Hold	5,486	–	–	﹤0.01%	1926
2024 Q2	$59K	Hold	5,486	–	–	﹤0.01%	1951
2024 Q1	$82K	Hold	5,486	–	–	﹤0.01%	1966
2023 Q4	$99K	Hold	5,486	–	–	﹤0.01%	1951
2023 Q3	$95K	Buy	5,486 +3,615	+193%	+$62.7K	﹤0.01%	1972
2023 Q2	$34K	Hold	1,871	–	–	﹤0.01%	2052
2023 Q1	$50K	Hold	1,871	–	–	﹤0.01%	2066
2022 Q4	$36K	Buy	+1,871	New	+$39.1K	﹤0.01%	2145
2022 Q2	–	Sell	-665	Closed	-$5K	–	2457
2022 Q1	$5K	Hold	665	–	–	﹤0.01%	2468
2021 Q4	$9K	Hold	665	–	–	﹤0.01%	2454
2021 Q3	$11K	Hold	665	–	–	﹤0.01%	2502
2021 Q2	$19K	Hold	665	–	–	﹤0.01%	2491
2021 Q1	$26K	Hold	665	–	–	﹤0.01%	2466
2020 Q4	$15K	Buy	+665	New	+$16.7K	﹤0.01%	2572

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Canada Life's PLRX Position: Q2 2025 in Review

Canada Life sold out of Pliant Therapeutics (PLRX) in Q2 2025, closing a stake of 5,486 shares — an estimated $7K sold.

Canada Life first reported a position in PLRX in Q4 2020 and held it in 16 quarters. The position peaked at $99K in Q4 2023. 114 funds tracked by Wall St. Rank hold PLRX as of Q2 2025.

Canada Life reported no remaining Pliant Therapeutics position as of Q2 2025 after selling out during the quarter.
Canada Life sold 5,486 Pliant Therapeutics shares in Q2 2025, an estimated $7K.
Canada Life first reported a position in Pliant Therapeutics in Q4 2020 and held it in 16 quarters.
Canada Life's Pliant Therapeutics position peaked at $99K in Q4 2023.
114 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2025.

Based on Canada Life's 13F filing for Q2 2025, filed 15 Aug 2025.